Professor and medical director, Radiation Oncology University of Chicago
Radiation Oncology
Dr. Daniel J. Haraf, MD
|
|
Give Review
Daniel Haraf is an expert in the field of Radiation Oncology. He received awards:"America's Top Doctors", "Chicago Magazine: Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Daniel Haraf is a published doctor. He published 49 publications, including: 'Response-Adapted Volume De-escalation (RAVD) in Locally Advanced Head and Neck Cancer.' Daniel Haraf is registered with Medicare.
Publications
- Response-Adapted Volume De-escalation (RAVD) in Locally Advanced Head and Neck Cancer.
- Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
- Race and competing mortality in advanced head and neck cancer.
- Lymph node density - Prognostic value in head and neck cancer.
- A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing ...
- Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
- Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer.
- Chemoradiation for patients with large-volume laryngeal cancers.
- Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
- Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
- Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
- Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer.
- Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.
- Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
- Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
- Chemoradiation for patients with advanced oral cavity cancer.
- Predictors of competing mortality in advanced head and neck cancer.
- Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.
- Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
- Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
- Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
- An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.
- Free-flap reconstruction in the doubly irradiated patient population.
- Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
- Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
- Aspiration in chemoradiated patients with head and neck cancer.
- A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
- Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer.
- Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.
- Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
- A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
- High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter pha...
- Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
- Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation.
- Planned post-chemoradiation neck dissection: significance of radiation dose.
- Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
- Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
- Reirradiation of recurrent head and neck cancers with curative intent.
- Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head...
- Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
- Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
- Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
- Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a criti...
- Is patient travel distance associated with survival on phase II clinical trials in oncology?
- Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin ...
- Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanc...
- Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
- Reirradiation: a potentially curative approach to locally or regionally recurrent head and neck cancer.
Schools
Rosalind Franklin University Of Medicine ScienceThe Chicago Medical School
Michael Reese
Doctors Specialties
- Internal Medicine
- Radiation Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Chicago Magazine: Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of Chicago -
Rosalind Franklin University of Medicine and Science
Hospital
-
University of Chicago Medical Center -
University of Illinois Hospital & Health Sciences System -
Jesse Brown Veterans Affairs Medical Center
Drug Facts
| NPI NUMBER | 1356400899 | |
| NPPES Provider LastName | HARAF | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 606371447 | |
| NPPES Provider State | IL | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 32.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356400899 |
| Last Name Of The Provider | HARAF |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. William R. Harper, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fernando D. Goldenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David O. Meltzer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rita M. Forster, MD |
|
|
Dr. Azhar M. Awan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chad T. Whelan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven J. Chmura, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Samuel Hellman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Howard J. Halpern, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Harold G. Sutton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip P. Connell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander C. Perez, MD
This Doctor is OpenDoctor Recommended.
|